MINIVELLE (estradiol) by Noven Pharmaceuticals is estrogen receptor agonists [moa]. First approved in 2012.
Drug data last refreshed 32m ago · AI intelligence enriched 5h ago
MINIVELLE is a transdermal estradiol film delivering estrogen via extended-release technology, approved in 2012 for hormone replacement therapy. It works as an estrogen receptor agonist to alleviate menopausal symptoms and bone health concerns in postmenopausal women. The transdermal delivery system provides steady systemic estradiol levels with improved tolerability compared to oral formulations.
Peak-stage product with modest Part D utilization (3,134 claims in 2023) operating in a highly competitive market (8/10 pressure), suggesting stable but not growth-driven commercial teams.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on MINIVELLE at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
Working on MINIVELLE offers stable career opportunities primarily in manufacturing, quality assurance, and regulatory compliance—reflecting a mature product with 11 linked roles. The approaching LOE timeline makes this ideal for professionals seeking hands-on operational experience in formulation and supply-chain excellence rather than product launch excitement.
11 open roles linked to this drug